Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM

NCT02058147 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1170

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: Insulin glargine/lixisenatide Fixed Ratio Combination
DRUG: Insulin glargine (HOE901)
DRUG: Lixisenatide (AVE0010)
DRUG: Metformin

Sponsor

Sanofi